Decitabine

Drug Profile

Decitabine

Alternative Names: 127716; 2'-deoxy-5-azacytidine; 2353-33-5; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 5-aza-2'-deoxycytidine; DAC; Dacogen; Decitabine mesylate; Deoxycytidine; Dezocitidine; E 7373; NSC-127716

Latest Information Update: 08 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Indiana University; SuperGen
  • Developer Eisai Co Ltd; HOVON Foundation; Janssen-Cilag; Otsuka Pharmaceutical; Sidney Kimmel Cancer Center; Xian-Janssen
  • Class Antineoplastics; Aza compounds; Deoxyribonucleosides; Pyrimidine nucleosides; Ribonucleosides; Small molecules
  • Mechanism of Action DNA methylation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia; Sickle cell anaemia; Myelodysplastic syndromes; Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Acute myeloid leukaemia; Chronic myeloid leukaemia; Myelodysplastic syndromes
  • Phase I/II Ovarian cancer
  • Phase I Liver cancer

Most Recent Events

  • 19 Jul 2017 Otsuka America Pharmaceutical terminates a phase I trial due to noncompliance to the DSMP in Acute myeloid leukaemia (Combination therapy, Newly diagnosed, Second-line therapy) in USA (IV) (NCT03063944)
  • 01 Jul 2017 Janssen completes a phase I trial in Liver cancer (Metastatic disease, Inoperable/Unresectable) in Belgium (IV) (NCT02316028)
  • 20 Apr 2017 The University of Southern California, in collaboration with National Cancer Institute initiates enrolment in a phase II trial for Acute-myeloid-leukaemia, Chronic-myeloid-leukaemia and Myelodysplastic-syndromes (Combination Therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (NCT03146871)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top